First-line treatment for chronic myeloid leukemia: Dasatinib, nilotinib, or imatinib

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Wei, Guoqing ^a,b   Rafiyath, Shamudheen ^b   Liu, Delong ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; AP 24534; BCR ABL PROTEIN; BOSUTINIB; DANUSERTIB; DASATINIB; DCC 2036; DCC 2157; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; OMACETAXINE; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TOZASERTIB; UNCLASSIFIED DRUG; XL 228; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; EYELID EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; LEUKEMIA; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; POINT MUTATION; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 78649325874     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-47     Document Type: Review

References (66)

1. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. M Deininger SG O'Brien F Guilhot JM Goldman A Hochhaus TP Hughes JP Radich AK Hatfield M Mone J Filian J Reynolds I Gathmann RA Larson BJ Druker, Blood 2009 114 Suppl 462 (abstract 1126)
2. Tyrosine kinase inhibitors: the first decade. M Agrawal RJ Garg J Cortes A Quintas-Cardama, Curr Hematol Malig Rep 2010 5 70 80 10.1007/s11899-010-0045-y 20425399
3. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. P le Coutre M Schwarz TD Kim, Clin Cancer Res 2010 16 1771 1780 10.1158/1078-0432.CCR-09-2760 20197479
4. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. G Rosti F Palandri F Castagnetti M Breccia L Levato G Gugliotta A Capucci M Cedrone C Fava T Intermesoli GR Cambrin F Stagno M Tiribelli M Amabile S Luatti A Poerio S Soverini N Testoni G Martinelli G Alimena F Pane G Saglio M Baccarani, Blood 2009 114 4933 4938 10.1182/blood-2009-07-232595 19822896
5. First-line therapy for chronic myeloid leukemia: new horizons and an update. G Saglio M Baccarani, Clin Lymphoma Myeloma Leuk 2010 10 169 176 10.3816/CLML.2010.n.026 20511160
6. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. T O'Hare DK Walters EP Stoffregen T Jia PW Manley J Mestan SW Cowan-Jacob FY Lee MC Heinrich MW Deininger BJ Druker, Cancer Res 2005 65 4500 4505 10.1158/0008-5472.CAN-05- 0259 15930265
7. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. E Weisberg PW Manley W Breitenstein J Bruggen SW Cowan-Jacob A Ray B Huntly D Fabbro G Fendrich E Hall-Meyers AL Kung J Mestan GQ Daley L Callahan L Catley C Cavazza M Azam D Neuberg RD Wright DG Gilliland JD Griffin, Cancer Cell 2005 7 129 141 10.1016/j.ccr.2005.01.007 15710326
8. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. M Puttini AM Coluccia F Boschelli L Cleris E Marchesi A Donella-Deana S Ahmed S Redaelli R Piazza V Magistroni F Andreoni L Scapozza F Formelli C Gambacorti-Passerini, Cancer Res 2006 66 11314 11322 10.1158/0008-5472.CAN-06-1199 17114238
9. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. S Redaelli R Piazza R Rostagno V Magistroni P Perini M Marega C Gambacorti-Passerini F Boschelli, J Clin Oncol 2009 27 469 471 10.1200/JCO.2008.19.8853 19075254
10. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. JS Tokarski JA Newitt CY Chang JD Cheng M Wittekind SE Kiefer K Kish FY Lee R Borzillerri LJ Lombardo D Xie Y Zhang HE Klei, Cancer Res 2006 66 5790 5797 10.1158/0008-5472.CAN-05-4187 16740718
11. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. N Vajpai A Strauss G Fendrich SW Cowan-Jacob PW Manley S Grzesiek W Jahnke, J Biol Chem 2008 283 18292 18302 10.1074/jbc.M801337200 18434310
12. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. H Kantarjian NP Shah A Hochhaus J Cortes S Shah M Ayala B Moiraghi Z Shen J Mayer R Pasquini H Nakamae F Huguet C Boque C Chuah E Bleickardt MB Bradley-Garelik C Zhu T Szatrowski D Shapiro M Baccarani, N Engl J Med 2010 362 2260 2270 10.1056/NEJMoa1002315 20525995
13. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. JE Cortes D Jones S O'Brien E Jabbour F Ravandi C Koller G Borthakur B Walker W Zhao J Shan H Kantarjian, J Clin Oncol 2010 28 398 404 10.1200/JCO.2009.25.4920 20008620
14. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. G Saglio DW Kim S Issaragrisil CP le G Etienne C Lobo R Pasquini RE Clark A Hochhaus TP Hughes N Gallagher A Hoenekopp M Dong A Haque RA Larson HM Kantarjian, N Engl J Med 2010 362 2251 2259 10.1056/NEJMoa0912614 20525993
15. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. JE Cortes D Jones S O'Brien E Jabbour M Konopleva A Ferrajoli T Kadia G Borthakur D Stigliano J Shan H Kantarjian, J Clin Oncol 2010 28 392 397 10.1200/JCO.2009.25.4896 20008621
16. Adherence to medication. L Osterberg T Blaschke, N Engl J Med 2005 353 487 497 10.1056/NEJMra050100 16079372
17. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. L Noens MA van Lierde R De Bock G Verhoef P Zachee Z Berneman P Martiat P Mineur K Van Eygen K MacDonald S De Geest T Albrecht I Abraham, Blood 2009 113 5401 5411 10.1182/blood-2008-12-196543 19349618
18. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. D Marin A Bazeos FX Mahon L Eliasson D Milojkovic M Bua JF Apperley R Szydlo R Desai K Kozlowski C Paliompeis V Latham L Foroni M Molimard A Reid K Rezvani H de Lavallde C Guallar J Goldman JS Khorashad, J Clin Oncol 2010 28 2381 2388 10.1200/JCO.2009.26.3087 20385986
19. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. T Darkow HJ Henk SK Thomas W Feng JF Baladi GA Goldberg A Hatfield J Cortes, Pharmacoeconomics 2007 25 481 496 10.2165/00019053-200725060-00004 17523753
20. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. JE Cortes M Baccarani F Guilhot BJ Druker S Branford DW Kim F Pane R Pasquini SL Goldberg M Kalaycio B Moiraghi JM Rowe E Tothova SC De m rudoltz R Yu T Krahnke HM Kantarjian JP Radich TP Hughes, J Clin Oncol 2010 28 424 430 10.1200/JCO.2009.25.3724 20008622
21. Declining rates of adverse events (AEs), rare occurrence of serious AEs, and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia in chronic phase initially treated with imatinib in the international randomized study of interferon vs STI571 (IRIS). HM Kantarjian RA Larson F Guilhot SG O'Brien BJ Druker on Behalf of IRIS Study Group, Blood 2006 108 Suppl abstract 2136
22. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. HM Kantarjian FJ Giles KN Bhalla J Pinilla-Ibarz RA Larson N Gattermann OG Ottmann A Hochhaus JP Radich G Saglio TP Hughes G Martinelli DW Kim Y Shou NJ Gallagher J Wang J Cortes-Franco M Baccarani PD Coutre, Blood 2009 114 Suppl abstract 1129
23. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia receiving 100 mg of dasatinib once daily. NP Shah JE Cortes CA Schiffer P le Coutre E Bahceci A Lambert G Saglio, J Clin Oncol 2010 28 Suppl abstract 6512
24. Severe toxicity of skin rash, fever, and diarrhea associated with imatinib:case report and review of skin toxicities associated with tyrosine kinase inhibitors. X Huang S Patel N Ahmed K Seiter D Liu, Drug Design, Development and Therapy 2008 2 215 219
25. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes JJ Cornelissen T Fischer A Hochhaus T Hughes K Lechner JL Nielsen P Rousselot J Reiffers G Saglio J Shepherd B Simonsson A Gratwohl JM Goldman H Kantarjian K Taylor G Verhoef AE Bolton R Capdeville BJ Druker, N Engl J Med 2003 348 994 1004 10.1056/NEJMoa022457 12637609 (Pubitemid 36302244)
26. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. D Masiello G Gorospe AS Yang, J Hematol Oncol 2009 2 46 10.1186/1756-8722-2-46 19909541
27. New dosing schedules of dasatinib for CML and adverse event management. SF Wong, J Hematol Oncol 2009 2 10 10.1186/1756-8722-2-10 19236716
28. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. RA Larson PD Le Coutre J Reiffers TP Hughes G Saglio P Edrich A Hoenekopp NJ Gallagher H Kantarijan A Hochhaus, J Clin Oncol 2010 28 Suppl abstract 6501
29. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. R Kerkela L Grazette R Yacobi C Iliescu R Patten C Beahm B Walters S Shevtsov S Pesant FJ Clubb A Rosenzweig RN Salomon RA Van Etten J Alroy JB Durand T Force, Nat Med 2006 12 908 916 10.1038/nm1446 16862153
30. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. A Hatfield S Owen PR Pilot, Nat Med 2007 13 13 16 10.1038/nm0107-13a 17206118
31. Congestive heart failure is a rare event in patients receiving imatinib therapy. E Atallah JB Durand H Kantarjian J Cortes, Blood 2007 110 1233 1237 10.1182/blood-2007-01-070144 17449798
32. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. M Breccia L Cannella A Frustaci C Stefanizzi A Levi G Alimena, Leuk Res 2008 32 835 836 10.1016/j.leukres.2007.08. 016 17905431
33. SPRYCEL® prescribing information (US), revised October 2010. Bristol-Myers Squibb
34. Tasigna (nilotinib) US prescribing information, revised June 2010. Novartis
35. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. H Kantarjian F Giles L Wunderle K Bhalla S O'Brien B Wassmann C Tanaka P Manley P Rae W Mietlowski K Bochinski A Hochhaus JD Griffin D Hoelzer M Albitar M Dugan J Cortes L Alland OG Ottmann, N Engl J Med 2006 354 2542 2551 10.1056/NEJMoa055104 16775235 (Pubitemid 43882350)
36. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Z Xu S Cang T Yang D Liu, Hematology Reviews 2009 1 4
37. An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. C Gambacorti-Passerini DW Kim HM Kantarjian TH Brummendorf I Dyagil L Griskevicius H Malhotra YT Goh JY Wang K Gogat J Cortes, Blood 2010 116 Suppl abstract 208 20647567
38. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. A Quintas-Cardama H Kantarjian F Ravandi S O'Brien D Thomas G Vidal-Senmache W Wierda S Kornblau J Cortes, Cancer 2009 115 2482 2490 10.1002/cncr.24257 19280591
39. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. MP Gratacap V Martin MC Valera S Allart C Garcia P Sie C Recher B Payrastre, Blood 2009 114 1884 1892 10.1182/blood-2009-02-205328 19494352
40. Dasatinib compared to imatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase: Twelve-month efficacy and safety from the phase III DASISION study. H Kantarjian NP Shah A Hochhaus JE Cortes S Shah M Ayala B Moiraghi M Bradley-Garelik C Zhu M Baccarani, J Clin Oncol 2010 28 suppl abstract LBA6500
41. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. PJ Bosma JR Chowdhury C Bakker S Gantla BA de BA Oostra D Lindhout GN Tytgat PL Jansen RP Oude Elferink, N Engl J Med 1995 333 1171 1175 10.1056/NEJM199511023331802 7565971
42. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. G Monaghan M Ryan R Seddon R Hume B Burchell, Lancet 1996 347 578 581 10.1016/S0140-6736(96)91273-8 8596320
43. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. JB Singer Y Shou F Giles HM Kantarjian Y Hsu AS Robeva P Rae A Weitzman JM Meyer M Dugan OG Ottmann, Leukemia 2007 21 2311 2315 10.1038/sj.leu.2404827 17611564
44. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). JE Cortes HM Kantarjian TH Brummendorf HJ Khoury DW Kim A Turkina A Volkert J Wang S Arkin C Gambacorti-Passerini, J Clin Oncol 2010 28 Suppl abstract 6502
45. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. S Soverini S Colarossi A Gnani F Castagnetti G Rosti C Bosi S Paolini M Rondoni PP Piccaluga F Palandri P Giannoulia G Marzocchi S Luatti N Testoni I Iacobucci D Cilloni G Saglio M Baccarani G Martinelli, Haematologica 2007 92 401 404 10.3324/haematol.10822 17339191
46. Resistance to tyrosine kinase inhibitors in Philadelphia chromosome-positive leukemias: which mutations matter? S Soverini M Baccarani I Iacobucci G Martinelli, Clin Leukemia 2008 1 223 228 10.3816/CLK.2007.n.012
47. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. JS Khorashad LH de JF Apperley D Milojkovic AG Reid M Bua R Szydlo E Olavarria J Kaeda JM Goldman D Marin, J Clin Oncol 2008 26 4806 4813 10.1200/JCO.2008.16.9953 18645191
48. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP). FE Nicolini S Corm QH Le N Sorel S Hayette D Bories T Leguay L Roy S Giraudier M Tulliez T Facon FX Mahon JM Cayuela P Rousselot M Michallet C Preudhomme F Guilhot C Roche-Lestienne, Leukemia 2006 20 1061 1066 10.1038/sj.leu.2404236 16642048
49. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. HA Bradeen CA Eide KJ Johnson SG Willis FY Lee BJ Druker MW Deininger, Blood 2006 108 2332 2338 10.1182/blood-2006-02-004580 16772610
50. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. E Jabbour H Kantarjian D Jones M Breeden G Garcia-Manero S O'Brien F Ravandi G Borthakur J Cortes, Blood 2008 112 53 55 10.1182/blood-2007-11-123950 18403620
51. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. FE Nicolini S Hayette S Corm E Bachy D Bories M Tulliez F Guilhot L Legros F Maloisel JJ Kiladjian FX Mahon QH Le M Michallet C Roche-Lestienne C Preudhomme, Haematologica 2007 92 1238 1241 10.3324/haematol.11369 17768119
52. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. FJ Giles J Cortes D Jones D Bergstrom H Kantarjian SJ Freedman, Blood 2007 109 500 502 10.1182/blood-2006-05-025049 16990603
53. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation. J Cortes R Paquette M Talpaz J Pinilla E Asatiani M Wetzler JH Lipton C Kasap LA Bui DO Clary N Shah, Blood 2008 112 Suppl abstract 3232
54. Interim results from a phase I clinical trial of the BCR-ABL inhibitor XL228 in drug-resistant Ph+ leukemias. P Shah E Asatiani J Cortes RL Paquette J Pinilla-Ibarz C Kasap LA Bui Y Yaron DO Clary M Talpaz, Haematologica 2008 93 s1 47 48 (abstract 120)
55. PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. RL Paquette NP Shah CL Sawyers G Martinelli N John M Chalukya M Rocchetti C Fiocchi S Comis L Capolongo B Laffranchi, Blood 2007 110 Suppl abstract 1030
56. Danusertib (formerly PHA-739358) - a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. A Gontarewicz TH Brummendorf, Recent Results Cancer Res 2010 184 199 214 full-text 20072840
57. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. A Gontarewicz S Balabanov G Keller R Colombo A Graziano E Pesenti D Benten C Bokemeyer W Fiedler J Moll TH Brummendorf, Blood 2008 111 4355 4364 10.1182/blood-2007-09-113175 18268096
58. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. T O'hare WC Shakespeare X Zhu CA Eide VM Rivera F Wang LT Adrian T Zhou WS Huang Q Xu CA Metcalf JW Tyner MM Loriaux AS Corbin S Wardwell Y Ning JA Keats Y Wang R Sundaramoorthi M Thomas D Zhou J Snodgrass L Commodore TK Sawyer DC Dalgarno MW Deininger BJ Druker T Clackson, Cancer Cell 2009 16 401 412 10.1016/j.ccr.2009. 09.028 19878872
59. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. J Cortes M Talpaz M Deininger N Shah IW Flinn MJ Mauro T O'Hare N Spinos S Hu L Berk N Narasimhan VM Rivera T Clackson F Haluska HM Kantarjian, Blood 2009 114 Suppl 267 (abstract 643)
60. Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML). VM Rivera Q Xu F Wang J Snodgrass T O'Hare AS Corbin J Keats S Lamore Y Ning S Wardwell K Russian M Broudy WC Shakespeare BJ Druker JD Iuliucci T Clackson, Blood 2007 110 Suppl abstract 1032
61. DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model. RA Van Etten WW Chan VM Zaleskas P Evangelista K Lazarides C Peng S Li SC Wise P Petillo DL Flynn, Blood 2007 110 Suppl abstract 463
62. Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I. RA Van Etten WW Chan VM Zaleskas C Walz P Evangelista K Lazarides M Betancur S Wise PA Petillo DL Flynn, Blood 2008 112 Suppl abstract 576
63. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Y Chen Y Hu S Michaels D Segal D Brown S Li, Leukemia 2009 23 1446 1454 10.1038/leu.2009.52 19322212
64. Omacetaxine mepesuccinate - a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. A Quintas-Cardama J Cortes, IDrugs 2008 11 356 372 18465678
65. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Y Chen C Peng C Sullivan D Li S Li, Anticancer Agents Med Chem 2010 10 111 115 20184539
66. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients with the T315I mutation: data from an ongoing phase II/III trial. JE Cortes HJ Khoury S Corm F Nicolini T Schenk D Jones A Hochhaus AR Craig E Humphriss H Kantarjian Study Group, J Clin Oncol 2009 27 Suppl abstract 7008